|
Cognition Therapeutics inc (NASDAQ: CGTX) |
|
Cognition Therapeutics inc
CGTX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Cognition Therapeutics Inc 's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 13.31 %
Cognition Therapeutics Inc net loss increased from $-7 millions, to $-10 millions in III. Quarter 2024,
• More on CGTX's Growth
|
|
Cognition Therapeutics Inc realized a net loss in trailing twelve months.
Cognition Therapeutics Inc realized cash reduction of $ -0.27 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.59.
• More on CGTX's Valuation
|
|
|
|
|
Cognition Therapeutics Inc realized net loss in trailing twelve months.
Cognition Therapeutics Inc realized cash outflow of $ -0.27per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.59.
Cognition Therapeutics Inc Price to Book Ratio is at 1.9 lower than Industry Avg. of 383.35. and higher than S&P 500 Avg. of 0.01
• More on CGTX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com